Diane Provencher

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Medicine, Genetics, Oncology +17

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Annals of Oncology · 2019 · 840 citations · Full text

Medicine, Oncology, Pharmacology +15

Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary

Sohrab P. Shah, Martin Köbel, Janine Senz et al. · New England Journal of Medicine · 2009 · 771 citations · Full text

Medicine, Genetics, Oncology +17